Get the Stockscreener App
156.49
3.37%
-5.45
After Hours:
155.25
-1.24
-0.79%
Neurocrine Biosciences Inc stock is traded at $156.49, with a volume of 2.09M.
It is down -3.37% in the last 24 hours and down -11.64% over the past month.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
See More
Previous Close:
$161.94
Open:
$159.74
24h Volume:
2.09M
Relative Volume:
1.66
Market Cap:
$15.91B
Revenue:
$3.10B
Net Income/Loss:
$668.60M
P/E Ratio:
24.06
EPS:
6.5044
Net Cash Flow:
$831.30M
1W Performance:
-3.10%
1M Performance:
-11.64%
6M Performance:
+27.12%
1Y Performance:
+21.41%
1-Day Range:
$154.86
$159.98
1-Week Range:
$154.86
$165.46
52-Week Range:
$122.14
$186.12
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Name
Neurocrine Biosciences Inc
Sector
Phone
(858) 617-7600
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
156.49 | 16.46B | 3.10B | 668.60M | 831.30M | 6.5044 |
TAK
Takeda Pharmaceutical Co Adr
|
17.41 | 55.82B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.80 | 43.73B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.74 | 42.51B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
73.54 | 31.14B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
511.72 | 22.11B | 3.17B | 1.29B | 1.01B | 27.09 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-21-25 | Initiated | Citigroup | Buy |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Apr-15-25 | Upgrade | Needham | Hold → Buy |
| Apr-14-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-29-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-24-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-13-23 | Resumed | Citigroup | Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-21-23 | Reiterated | Mizuho | Neutral |
| Jul-24-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Jul-06-23 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| May-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-14-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-22 | Initiated | UBS | Buy |
| Sep-26-22 | Initiated | Wells Fargo | Equal Weight |
| Jun-06-22 | Resumed | Jefferies | Buy |
| Mar-03-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-25-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-18-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-21 | Initiated | BMO Capital Markets | Underperform |
| Nov-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Aug-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-18-21 | Resumed | Goldman | Neutral |
| May-06-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-02-21 | Initiated | Raymond James | Outperform |
| Sep-30-20 | Initiated | The Benchmark Company | Hold |
| Aug-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-29-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-09-20 | Initiated | Wedbush | Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-24-20 | Initiated | William Blair | Outperform |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Feb-05-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-07-19 | Initiated | RBC Capital Mkts | Outperform |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-05-19 | Initiated | Guggenheim | Neutral |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-22-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Feb-06-19 | Reiterated | BofA/Merrill | Buy |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-13-18 | Initiated | Goldman | Buy |
| Nov-21-18 | Initiated | Canaccord Genuity | Buy |
View All
Neurocrine Biosciences Inc Stock (NBIX) Latest News
NBIX Stock Slips As $2.9B Soleno Deal Triggers Fresh Drug Safety Warnings - finance.yahoo.com
Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug - Reuters
Why is Neurocrine Biosciences stock sliding today? By Investing.com - Investing.com Canada
Why Neurocrine Biosciences (NBIX) Stock Is Down Today - Quiver Quantitative
What's Going On With Neurocrine Biosciences Stock On Wednesday? - TradingView
Neurocrine down on safety events linked to Vykat (NBIX:NASDAQ) - Seeking Alpha
Neurocrine Biosciences Shares Drop Amid Vykat Safety Reports - StockInvest.us
Neurocrine Biosciences shares fall amid Vykat safety concerns - finance.yahoo.com
Neurocrine Biosciences stock falls on Vykat safety concerns - Investing.com
Neurocrine study shows Ingrezza improved tardive dyskinesia symptoms - Investing.com
Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia - PR Newswire
Why is Neurocrine Biosciences stock down today? By Investing.com - Investing.com Canada
Handelsbanken Fonder AB Has $34.70 Million Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Liquidity Mapping Around (NBIX) Price Events - Stock Traders Daily
Is Neurocrine Biosciences (NBIX) Fully Valued As It Enters Phase 1 Obesity Testing? - Sahm
Neurocrine Initiates Phase I Trial of Triple Agonist NBIP-’1968 for Obesity - BioPharma APAC
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: A 30% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews
Bank of America Corp DE Boosts Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Assenagon Asset Management S.A. Has $37.52 Million Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Stock Rating Lowered by Wall Street Zen - MarketBeat
Neurocrine Biosciences, Inc. (NB3.F) Analyst insights, Price targets and Recommendations - Yahoo Finance Australia
Neurocrine Biosciences, Inc. $NBIX Shares Purchased by Cetera Investment Advisers - MarketBeat
Healthcare Stocks Investors Are Watching For Steady Demand After Weak US Jobs Data - Sahm
How Stronger Q2 Results and New Equity Capacity Will Impact Neurocrine Biosciences (NBIX) Investors - simplywall.st
Neurocrine starts phase 1 trial of obesity drug candidate - Investing.com
Neurocrine’s Investigational Obesity Drug Targets Three Receptors - Stock Titan
Neurocrine Biosciences, Inc. $NBIX Stake Boosted by PKO BP BANKOWY Universal Pension Society JSC - MarketBeat
Zacks Research Downgrades Neurocrine Biosciences (NASDAQ:NBIX) to Hold - MarketBeat
Neurocrine Biosciences (NBIX) CSO Jude Onyia makes bona fide stock gift - Stock Titan
Neurocrine Biosciences (NASDAQ:NBIX): A Value Stock With Quality Behind the Discount - ChartMill
The Manufacturers Life Insurance Company Trims Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Quantinno Capital Management LP Buys 42,508 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
BDF Gestion Invests $2 Million in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Private Client Services LLC Trims Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Purchased by Pacer Advisors Inc. - MarketBeat
Amundi Raises Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
H.C. Wainwright reiterates Neurocrine Bio stock rating on pipeline progress - Investing.com
H.C. Wainwright reiterates Neurocrine Bio stock rating on pipeline progress By Investing.com - Investing.com Nigeria
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: A Deep Dive into a 26.55% Potential Upside - DirectorsTalk Interviews
Neurocrine Biosciences, Inc. $NBIX Shares Bought by Royal Bank of Canada - MarketBeat
Perceptive Advisors LLC Sells 266,000 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Enterprise value to revenue forward of Neurocrine Biosciences, Inc. – SWB:NB3 - TradingView
Arete Wealth Advisors LLC Invests $3.04 Million in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Guggenheim raises Neurocrine Bio stock price target on Ingrezza beat By Investing.com - Investing.com Nigeria
Neurocrine Biosciences (NBIX) Stock Slides As Growth Spending Steals Focus - simplywall.st
Neurocrine Biosciences, Inc. Revenue Breakdown – NASDAQ:NBIX - TradingView
JPMorgan Chase & Co. Boosts Neurocrine Biosciences Inc (NBIX) St - GuruFocus
Neurocrine Biosciences (NBIX) quantifies Soleno acquisition and VYKAT XR impact - Stock Titan
NEUROCRINE BIOSCIENCES INC 2026: Revenue $959M, EPS $1.39— 10-Q Summary - TradingView
Neurocrine Biosciences Q2 Earnings Call Highlights - MarketBeat
Neurocrine Biosciences, Inc. Stock 12‑Month Price Target Raised to $208.59, Implies 12% Upside - TradingView
Neurocrine Biosciences Inc Stock (NBIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
2.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):